18F-FDG PET与CT标准在纳武利尤单抗治疗非小细胞肺癌中的比较
该研究纳入72例晚期非小细胞肺癌患者,在纳武利尤单抗治疗前及4周期后行CT和18F-FDG PET评估,比较RECIST 1.1、irRC与PERCIST、imPERCIST的应答评估一致性及预测总生存的能力。结果显示CT与PET标准间一致性低,irRC能更可靠区分应答者与非应答者,但PERCIST和imPERCIST评估的部分代谢缓解在irRC判定为进展的患者中仍保持预后意义。
要点
- CT与PET标准评估纳武利尤单抗应答的一致性低。
- irRC较PET标准能更可靠区分应答者与非应答者。
- PERCIST和imPERCIST评估的部分代谢缓解在irRC进展患者中仍有预后价值。
核心结论
- 本研究不支持在非小细胞肺癌免疫检查点抑制剂治疗患者中常规使用18F-FDG PET评估应答,但代谢应答评估具有附加预后价值,可能改善治疗决策。
研究设计与样本
- 单中心扩展准入计划(NCT02475382)辅助试验,纳入72例晚期非小细胞肺癌患者,基线及4周期后行CT和18F-FDG PET评估,进展者2周期后确认。
主要发现
- CT与PET标准间一致性低:PERCIST与RECIST的κ值为0.346,imPERCIST与RECIST的κ值为0.355;PERCIST与irRC的κ值为0.128,imPERCIST与irRC的κ值为0.198。
- irRC能更可靠区分应答者与非应答者。
- PERCIST和imPERCIST评估的部分代谢缓解在irRC判定为进展的患者中仍保持预后意义。
关键数值与推荐
- CT应答采用RECIST 1.1和irRC评估。
- PET应答采用PERCIST和免疫治疗改良PERCIST评估。
临床怎么用
- 在非小细胞肺癌纳武利尤单抗治疗中,不应常规使用18F-FDG PET替代CT标准评估应答。
- 对irRC判定为进展的患者,可考虑结合PERCIST或imPERCIST评估的代谢缓解信息辅助预后判断和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of the peculiar mechanism of action of immune checkpoint inhibitors (ICIs), evaluation of the radiologic response to them in solid tumors presents many challenges. We aimed to compare evaluation of the first response to nivolumab by means of CT-based criteria with respect to 18F-FDG PET response criteria in non-small cell lung cancer (NSCLC) patients. Methods: Seventy-two patients with advanced NSCLC were recruited in a single-institution ancillary trial within the expanded-access program (NCT02475382) for nivolumab. Patients underwent CT and 18F-FDG PET at baseline and after 4 cycles (the first evaluation). In cases of progressive disease, an additional evaluation was performed after 2 further cycles to confirm progression. We evaluated the treatment response on CT using RECIST 1.1 and the immune-related response criteria (irRC) and on 18F-FDG PET using PERCIST and immunotherapy-modified PERCIST. The concordance between CT- and PET-based criteria and the capability of each method to predict overall survival were evaluated. Results: Forty-eight of 72 patients were evaluable for a first response assessment with both PET- and CT-based criteria. We observed low concordance between CT- and PET-based criteria (κ-value of 0.346 and 0.355 between PERCIST and imPERCIST and RECIST, respectively. κ-value of 0.128 and 0.198 between PERCIST and imPERCIST and irRC, respectively). Regarding overall survival, irRC could more reliably distinguish responders from nonresponders. However, thanks to the prognostic value of partial metabolic response assessed by both PERCIST and immunotherapy-modified PERCIST, PET-based response maintained prognostic significance in patients classified as having progressive disease on the basis of irRC. Conclusion: Even though the present study did not support the routine use of 18F-FDG PET in the general population of NSCLC patients treated with ICIs, the findings suggest that metabolic response assessment has added prognostic value, potentially improving therapeutic decision making.
引用
- Rossi G, Bauckneht M, Genova C, et al. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Nucl Med. 2019. PMID: 31806768. doi:10.2967/jnumed.119.233056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。